Marc L Berger

List of Publications by Citations

Source: https://exaly.com/author-pdf/9251039/marc-l-berger-publications-by-citations.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

3,585
citations

4.6
ext. papers

3,985
ext. citations

27
h-index
4.68
avg, IF

L-index

#	Paper	IF	Citations
57	Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 2815-22	27.4	825
56	Osteoporosis and fracture risk in women of different ethnic groups. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 185-94	6.3	380
55	Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 2222-30	6.3	246
54	Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force ReportPart I. Value in	3.3	236
53	Health, 2009, 12, 1044-52 A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. Journal of Rheumatology, 2002, 29, 804-12	4.1	150
52	Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. <i>Value in Health</i> , 2012 , 15, 217-30	3.3	120
51	Valuing reductions in on-the-job illness: \$presenteeismSfrom managerial and economic perspectives. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 469-85	2.4	117
50	Measuring the effects of work loss on productivity with team production. <i>Health Economics (United Kingdom)</i> , 2006 , 15, 111-23	2.4	117
49	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017 , 20, 1003-1008	3.3	113
48	A general model of the impact of absenteeism on employers and employees. <i>Health Economics</i> (United Kingdom), 2002 , 11, 221-31	2.4	102
47	CCl4-induced toxicity in isolated hepatocytes: the importance of direct solvent injury. <i>Hepatology</i> , 1986 , 6, 36-45	11.2	97
46	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , 2010 , 16, 467-71	2.1	90
45	A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. <i>Value in Health</i> , 2014 , 17, 143-56	3.3	77
44	Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol. <i>Biochemical Pharmacology</i> , 1988 , 37, 333-8	6	65
43	Opportunities and challenges in leveraging electronic health record data in oncology. <i>Future Oncology</i> , 2016 , 12, 1261-74	3.6	62
42	Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. <i>Menopause</i> , 2003 , 10, 412-9	2.5	49
41	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017 , 20, 1009-1022	3.3	47

(2004-2002)

40	Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1951-8	0.7	47
39	Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care, 2005, 11, 621-8	2.1	46
38	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019 , 22, 13-20	3.3	45
37	Treatment of migraine with rizatriptan: when to take the medication. <i>Headache</i> , 2002 , 42, 16-20	4.2	39
36	Comparative effectiveness: asking the right questions, choosing the right method. <i>Health Affairs</i> , 2005 , 24, 128-32	O	36
35	Optimizing the leveraging of real-world data to improve the development and use of medicines. <i>Value in Health</i> , 2015 , 18, 127-30	3.3	35
34	Toxicity of methylating agents in isolated hepatocytes. <i>Biochemical Pharmacology</i> , 1988 , 37, 3183-8	6	30
33	Big data, advanced analytics and the future of comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2014 , 3, 167-76	2.1	29
32	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. <i>American Journal of Health-System Pharmacy</i> , 2007 , 64, 637-4	3 ^{2.2}	28
31	Anoxic hepatocyte injury: role of reversible changes in elemental content and distribution. <i>Hepatology</i> , 1989 , 9, 219-28	11.2	27
30	How to present the business case for healthcare quality to employers. <i>Applied Health Economics and Health Policy</i> , 2005 , 4, 209-18	3.4	25
29	Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. <i>Clinical Therapeutics</i> , 2005 , 27, 960-9	3.5	22
28	Carbon tetrachloride-induced morphologic alterations in isolated rat hepatocytes. <i>Experimental and Molecular Pathology</i> , 1987 , 46, 245-57	4.4	21
27	Getting real performance out of pay-for-performance. Milbank Quarterly, 2008, 86, 435-57	3.9	19
26	Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. <i>American Journal of Cardiology</i> , 1996 , 77, 475-9	3	18
25	Scurvy as an initial manifestation of Whipple's disease. <i>Annals of Internal Medicine</i> , 1984 , 101, 58-9	8	16
24	Rapid halogenated hydrocarbon toxicity in isolated hepatocytes is mediated by direct solvent effects. <i>Toxicology</i> , 1987 , 45, 319-30	4.4	15
23	A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. <i>Preventing Chronic Disease</i> , 2004 , 1, A05	3.7	15

22	Big Data: transforming drug development and health policy decision making. <i>Health Services and Outcomes Research Methodology</i> , 2016 , 16, 92-102	1.6	15
21	Evidence synthesis and evidence-based decision making: related but distinct processes. <i>Medical Decision Making</i> , 2005 , 25, 487-9	2.5	14
20	Efficient patient identification strategies for women with osteoporosis. <i>Journal of Clinical Densitometry</i> , 1999 , 2, 223-30	3.5	14
19	Cost-Effectiveness Analysis. <i>Medical Care</i> , 2005 , 43, II-49	3.1	12
18	A Population-Based Approach to Asthma Disease Management. <i>Disease Management and Health Outcomes</i> , 2000 , 7, 179-186		12
17	A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996 , 1, 101-106	2.6	11
16	The role of private industry in pragmatic comparative effectiveness trials. <i>Journal of Comparative Effectiveness Research</i> , 2012 , 1, 147-56	2.1	10
15	Quality-of-life questionnaire for patients taking antihypertensive medication. <i>Clinical Therapeutics</i> , 1999 , 21, 1771-87	3.5	10
14	Growth in use of lipid-lowering therapies: are we targeting the right patients?. <i>American Journal of Managed Care</i> , 2002 , 8, 862-7	2.1	10
13	Effectiveness of antihyperlipidemic drug management in clinical practice. <i>Clinical Therapeutics</i> , 1999 , 21, 1973-87	3.5	9
12	The once and future application of cost-effectiveness analysis. <i>The Joint Commission Journal on Quality Improvement</i> , 1999 , 25, 455-61		9
11	Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. <i>Medical Care</i> , 2017 , 55, 244-251	3.1	8
10	Comparative effectiveness research: the view from a pharmaceutical company. <i>Pharmacoeconomics</i> , 2010 , 28, 915-22	4.4	7
9	Novel oral medication delivery system for famotidine. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 362-7	2.9	6
8	Toward Facilitated Self-Service in Health Care. New England Journal of Medicine, 2019, 380, 1891-1893	59.2	5
7	Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. <i>American Journal of Managed Care</i> , 2002 , 8, 937-46	2.1	5
6	Raising the bar of efficacy for drug approval requires an understanding of patient diversity. <i>Journal of Clinical Oncology</i> , 2010 , 28, e343-4; author reply e345	2.2	4
5	The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. <i>Medical Decision Making</i> , 2007 , 27, 364-79	2.5	4

LIST OF PUBLICATIONS

4	The Value of Disease Management. <i>Disease Management and Health Outcomes</i> , 2000 , 8, 181-184		4
3	Studies on calcium transport during carbon tetrachloride mediated hepatotoxicity in mice. <i>Biochemical Pharmacology</i> , 1988 , 37, 4584-6	6	4
2	Bone Mineral Density Thresholds for Pharmacologic Intervention to Prevent Fractures. <i>Obstetrical and Gynecological Survey</i> , 2004 , 59, 769-771	2.4	2
1	Disease Management: An Intermediate Step Toward Integrated and Coordinated Patient Care. <i>Disease Management: DM</i> , 2001 , 4, 173-178		1